Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A90249%2F23%3A00135351" target="_blank" >RIV/00216224:90249/23:00135351 - isvavai.cz</a>
Result on the web
<a href="https://test.uhkt.cz/clinical-trials/clinical-trials" target="_blank" >https://test.uhkt.cz/clinical-trials/clinical-trials</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023)
Original language description
Report No. 3 on the progress of the clinical evaluation of the EudraCT project 2018-004789-32, code UHKT-CAR19-01, 9.6.2022 - 8.6.2023: Development Safety Update Report: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-label, phase I study. (2023) Report No. 3 was prepared on the progress of the clinical evaluation 9/6/2022 - 8/6/2023: Development Safety Update Report 2023: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ acute lymphoblastic leukemia and non-Hodgkin lymphoma. A dose escalation, open-Iabel, phase I study: EudraCT project 2018-004789-32, code UHKT-CAR19-01.
Czech name
—
Czech description
—
Classification
Type
V<sub>souhrn</sub> - Summary research report
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Number of pages
4
Place of publication
Praha
Publisher/client name
ÚHKT PRAHA
Version
—